Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated 25Sep17 due to parent study insufficient efficacy. Not due to safety

Conditions

DRUG: 1 mg QD to 15 mg QD PF-06649751
DRUG: 3 mg QD to 15 mg QD PF-06649751
DRUG: 7 mg QD to 15 mg QD PF-06649751
DRUG: 15 mg QD PF-06649751
DRUG: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)
DRUG: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)
DRUG: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)
DRUG: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD

Pfizer